Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
InspireMD (NSPR)
NASDAQ:NSPR
Holding NSPR?
Track your performance easily
NSPR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.81 - $3.42
Previous Close$2.58
Volume19.65K
Average Volume (3M)22.52K
Market Cap
$67.30M
Enterprise Value$27.58M
Total Cash (Recent Filing)$40.40M
Total Debt (Recent Filing)$682.00K
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Mar 11, 2025EPS Estimate
-$0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.84
Shares Outstanding26,083,763
10 Day Avg. Volume46,242
30 Day Avg. Volume22,518
Standard Deviation1.06
R-Squared0.02
Alpha0.10
Financial Highlights & Ratios
Price to Book (P/B)1.66
Price to Sales (P/S)9.83
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.04
Enterprise Value/Gross Profit15.26
Enterprise Value/Ebitda-1.22
Forecast
1Y Price Target
$4.50Price Target Upside69.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
InspireMD News
PremiumCompany Announcements
InspireMD Inc. Reports Q3 2024 Financial Results
PremiumCompany Announcements
InspireMD Achieves Record Q3 Revenue with CGuard Success
PremiumCompany Announcements
InspireMD Expands with New Miami Headquarters
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NSPR FAQ
What was InspireMD’s price range in the past 12 months?
InspireMD lowest stock price was $1.81 and its highest was $3.42 in the past 12 months.
What is InspireMD’s market cap?
Currently, no data Available
When is InspireMD’s upcoming earnings report date?
InspireMD’s upcoming earnings report date is Mar 11, 2025 which is in 108 days.
How were InspireMD’s earnings last quarter?
InspireMD released its earnings results on Nov 12, 2024. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.04.
Is InspireMD overvalued?
According to Wall Street analysts InspireMD’s price is currently Undervalued.
Does InspireMD pay dividends?
InspireMD does not currently pay dividends.
What is InspireMD’s EPS estimate?
InspireMD’s EPS estimate is -$0.2.
How many shares outstanding does InspireMD have?
InspireMD has 26,083,763 shares outstanding.
What happened to InspireMD’s price movement after its last earnings report?
InspireMD reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went down -3.252%.
Which hedge fund is a major shareholder of InspireMD?
Currently, no hedge funds are holding shares in NSPR
---
InspireMD Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.17%
12-Months-Change
Fundamentals
Return on Equity
-66.75%
Trailing 12-Months
Asset Growth
0.92%
Trailing 12-Months
Company Description
InspireMD
InspireMD, Inc. is a medical device company, which engages in the development and commercialization of the stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Tel Aviv, Israel.
---
NSPR Earnings Call
Q3 2024
0:00 / 0:00
---
NSPR Stock 12 Month Forecast
Average Price Target
$4.50
▲(69.81% Upside)
Technical Analysis
Best Analysts Covering NSPR
1 Year
1 Year Success Rate
2/3 ratings generated profit
1 Year Average Return
+9.40%
assigned a buy rating 2 months ago
Copying Adam Maeder's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +9.40% per trade.
---